Nebivolol Ratiopharm (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Ratiopharm, is a beta‑blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering blood pressure and improving vascular tone.

GNH USA supplies Nebivolol Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker used in the management of cardiovascular blood‑pressure disorders. - Essential hypertension: reduces both systolic and diastolic blood pressure. - Isolated systolic hypertension: lowers elevated systolic pressure, especially in older adults. - Secondary hypertension: assists in controlling blood pressure when caused by other medical conditions. - Hypertension in patients with metabolic syndrome: improves vascular function while minimizing metabolic impact. - High‑risk hypertensive patients: contributes to overall cardiovascular risk reduction.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: especially on standing. - Fatigue: general tiredness during initial therapy. - Nasal congestion: mild blockage of nasal passages. - Diarrhea: loose stools without blood. - Bradycardia: heart rate below normal resting levels.

Serious or Rare Side Effects: - Severe bradycardia: may require medical attention. - Heart block: conduction abnormalities detectable on ECG. - Acute heart failure exacerbation: worsening of cardiac function. - Bronchospasm: difficulty breathing, particularly in patients with asthma. - Hypotension: marked drop in blood pressure causing faintness. - Allergic reactions: rash, itching, or swelling of face and throat.

Before initiating therapy, clinicians should evaluate patient history and comorbidities. - Cardiovascular disease: assess for bradycardia or heart block before use. - Asthma or chronic obstructive pulmonary disease: monitor for bronchospasm. - Diabetes mellitus: watch for masking of hypoglycaemic symptoms. - Liver impairment: consider dose adjustment as metabolism may be reduced. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): may cause severe heart block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Antihypertensive diuretics: risk of excessive blood‑pressure reduction. - Antidiabetic agents: possible masking of hypoglycaemia signs. - NSAIDs: may blunt antihypertensive effect. - Digoxin: monitor for increased plasma concentration. - Clonidine: abrupt withdrawal can cause rebound hypertension.